Price
$3.26-46.56%Social Signal Score
Analyst Ratings
37 analystsRevenue
$190.70M+7.44%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Samraat S. Raha
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 2,700
- Beta
- 1.68
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -0.84
Financials
Revenue
$190.70M+7.4%Net Income
$-43.20MEBITDA
$-26.00M-287.1%Free Cash Flow
$-10.40MEPS (diluted)
$-0.46Shares Outstanding (diluted)
94.80M+37.8%Operating Expenses
$165.90MCash & Debt
$115.20MReturn of Capital
$0.00Revenue by Segment (annual)
$753.20MDividend per Share
$1.75Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $824.50M | $-365.90M | $-3.96 |
| 2024 | $837.60M | $-127.30M | $-1.41 |
| 2023 | $753.20M | $-263.30M | $-3.18 |
| 2022 | $678.40M | $-112.00M | $-1.39 |
| 2021 | $690.60M | $-27.20M | $-0.35 |
| 2020 | $557.00M | $-223.70M | $-2.99 |
| 2019 | $638.60M | $-199.50M | $-2.69 |
| 2018 | $851.10M | $4.60M | $0.06 |
| 2017 | $743.70M | $133.30M | $1.89 |
| 2016 | $728.70M | $17.40M | $0.32 |
| 2015 | $740.50M | $117.20M | $1.79 |
| 2014 | $723.10M | $80.20M | $1.12 |
| 2013 | $778.20M | $176.20M | $2.33 |
| 2012 | $613.20M | $147.20M | $1.82 |
Valuation
MYGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-50.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·20d ago·Neutral
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, effective September 16, 2026.
View source ↗ - Newsbarrons.com·34d ago·Neutral
This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse. Piper Sandler cuts Myriad Genetics stock to Underweight, citing doubts about the genetic testing company's path to sustainable profitability.
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST. The presentation will be available through a live audio webcast link in the investor information section of Myriad's web…
View source ↗ - Newsgurufocus.com·58d ago·Negative
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law [url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
View source ↗ - Newsbusinesswire.com·58d ago·Negative
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law.
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $-0.16 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-0.25 vs $-0.06miss
- Tue, May 5$-0.09 vs $-0.06miss
- Mon, Feb 23$0.04 vs $-0.02beat
- Mon, Nov 3$-0.13 vs $-0.01miss
- Tue, Aug 5$0.05 vs $-0.01beat
- Tue, May 6$-0.03 vs $-0.05beat
Estimates and results for MYGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MYGN officers and directors.
- Bought
- $722k
- Sold
- $67k
5 trades
1 trade
- Kumar Rashmisold
- Bisaro Paulbought
- Raha Samraat S.bought
- Phanstiel S. Louisebought
- Phanstiel S. Louisebought
- Phanstiel S. Louisebought
94 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MYGN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.